Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

• Main Authors: Khunti, Kamlesh, Kosiborod, Mikhail, Kim, Dae Jung, Kohsaka, Shun, Lam, Carolyn S. P., Goh, Su-Yen, Chiang, Chern-En, Shaw, Jonathan E., Cavender, Matthew A., Tangri, Navdeep, Franch-Nadal, Josep, Holl, Reinhard W., Jørgensen, Marit E., Norhammar, Anna, Eriksson, Johan G., Zaccardi, Francesco, Karasik, Avraham, Magliano, Dianna J., Thuresson, Marcus, Chen, Hungta, Wittbrodt, Eric, Bodegård, Johan, Surmont, Filip, Fenici, Peter, Wilding, John P., Birkeland, Kåre, Carstensen, Bendix, Kendrick, Rachel, Belli, Wesley, Noguchi, Yusuke, Andersson-Sundell, Karolina, Kadir, Hanis Abdul, Ha, Kyoung Hwa, Lee, Jinhee, Chodick, Gabriel, Cohen, Cheli Melzer, Whitlock, Reid, Soriano, Lucia Cea, Cantero, Oscar Fernándex, Menzin, Jordan A., Guthrie, Matthew, Ilomaki, Jennie, Hoti, Fabian, Christopher, Solomon, Vehkala, Minna
• Other Authors: DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
• Format: Article
• Published: BioMed Central Ltd 2022
• Subjects: Cardiovascular outcomes; Heart failure; Sodium–glucose cotransporter-2 inhibitors; Type 2 diabetes
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/233558
• Institution: National University of Singapore

10.1186/s12933-021-01345-z